These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25085632)

  • 1. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.
    Subbiah V; Meric-Bernstam F; Mills GB; Shaw KR; Bailey AM; Rao P; Ward JF; Pagliaro LC
    J Hematol Oncol; 2014 Aug; 7():52. PubMed ID: 25085632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.
    Feldman DR; Patil S; Trinos MJ; Carousso M; Ginsberg MS; Sheinfeld J; Bajorin DF; Bosl GJ; Motzer RJ
    Cancer; 2012 Feb; 118(4):981-6. PubMed ID: 21792865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.
    Oechsle K; Honecker F; Cheng T; Mayer F; Czaykowski P; Winquist E; Wood L; Fenner M; Glaesener S; Hartmann JT; Chi K; Bokemeyer C; Kollmannsberger C
    Ann Oncol; 2011 Dec; 22(12):2654-2660. PubMed ID: 21415240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors.
    Feldman DR; Turkula S; Ginsberg MS; Ishill N; Patil S; Carousso M; Bosl GJ; Motzer RJ
    Invest New Drugs; 2010 Aug; 28(4):523-8. PubMed ID: 19547919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
    Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
    Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
    Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
    Feldman DR; Iyer G; Van Alstine L; Patil S; Al-Ahmadie H; Reuter VE; Bosl GJ; Chaganti RS; Solit DB
    Clin Cancer Res; 2014 Jul; 20(14):3712-20. PubMed ID: 24812411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium.
    Shaikh F; Stark D; Fonseca A; Dang H; Xia C; Krailo M; Pashankar F; Rodriguez-Galindo C; Olson TA; Nicholson JC; Murray MJ; Amatruda JF; Billmire D; Stoneham S; Frazier AL
    Cancer; 2021 Jan; 127(2):193-202. PubMed ID: 33079404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors.
    Maroto P; Huddart R; Garcia del Muro X; Horwich A; Paz Ares L; Aparicio J; Germa-Lluch JR
    Oncology; 2011; 80(3-4):219-22. PubMed ID: 21734411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series.
    Oing C; Hentrich M; Lorch A; Gläser D; Rumpold H; Ochsenreither S; Richter S; Dieing A; Zschäbitz S; Pereira RR; Bokemeyer C; Seidel C
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):449-455. PubMed ID: 31838576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of sunitinib in extraskeletal myxoid chondrosarcoma.
    Stacchiotti S; Pantaleo MA; Astolfi A; Dagrada GP; Negri T; Dei Tos AP; Indio V; Morosi C; Gronchi A; Colombo C; Conca E; Toffolatti L; Tazzari M; Crippa F; Maestro R; Pilotti S; Casali PG
    Eur J Cancer; 2014 Jun; 50(9):1657-64. PubMed ID: 24703573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational targeted therapies for the treatment of testicular germ cell tumors.
    Oing C; Kollmannsberger C; Oechsle K; Bokemeyer C
    Expert Opin Investig Drugs; 2016 Sep; 25(9):1033-43. PubMed ID: 27286362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect.
    Stacchiotti S; Negri T; Zaffaroni N; Palassini E; Morosi C; Brich S; Conca E; Bozzi F; Cassinelli G; Gronchi A; Casali PG; Pilotti S
    Ann Oncol; 2011 Jul; 22(7):1682-1690. PubMed ID: 21242589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
    Rutkowski P; Bylina E; Klimczak A; Switaj T; Falkowski S; Kroc J; Lugowska I; Brzeskwiniewicz M; Melerowicz W; Osuch C; Mierzejewska E; Wasielewski K; Woźniak A; Grzesiakowska U; Nowecki ZI; Siedlecki JA; Limon J
    BMC Cancer; 2012 Mar; 12():107. PubMed ID: 22439647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
    Papaetis GS; Syrigos KN
    BioDrugs; 2009; 23(6):377-89. PubMed ID: 19894779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of
    Timmerman DM; Eleveld TF; Gillis AJM; Friedrichs CC; Hillenius S; Remmers TL; Sriram S; Looijenga LHJ
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
    Polyzos A
    J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):261-6. PubMed ID: 17945482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
    Chau NG; Hotte SJ; Chen EX; Chin SF; Turner S; Wang L; Siu LL
    Ann Oncol; 2012 Jun; 23(6):1562-70. PubMed ID: 22080184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.